{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T19:48:11Z","timestamp":1792439291036,"version":"4.5.0"},"reference-count":0,"publisher":"SMW Supporting Association","issue":"10","license":[{"start":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:00:00Z","timestamp":1792368000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Swiss Med Wkly"],"abstract":"<jats:p>INTRODUCTION: The HeartMate 3 left ventricular assist device (LVAD) is an established therapy for advanced heart failure, yet contemporary real-world data from low- or medium-volume centres remain limited. We aimed to describe the characteristics, management and clinical outcomes of patients undergoing HeartMate 3 LVAD implantation at a Swiss tertiary centre.\nMETHODS: We conducted an observational study including consecutive adult patients who underwent HeartMate 3 implantation at Lausanne University Hospital between November 2015 and January 2026. Baseline characteristics, INTERMACS profiles, perioperative data, survival and LVAD-related complications were assessed. The primary outcome was survival on LVAD support. Comparisons by LVAD indication were pre-specified exploratory analyses (destination therapy vs bridge-to-transplant). Survival analyses on LVAD support, with heart transplantation or LVAD explantation treated as censoring events, were reported.\nRESULTS: A total of 100 patients (mean age 58 [standard deviation 12] years, 84% male, 29% destination therapy) underwent HeartMate 3 implantation. Ischaemic heart disease was the predominant aetiology (69%) and most patients (68%) were classified as INTERMACS profiles 3\u20134 at implantation. Over a median follow-up of 1.5 (IQR 0.5\u20133) years, 27 patients died on LVAD support, corresponding to a mortality incidence rate (IR) of 13.5 deaths per 100 patient-years, while 51 patients underwent heart transplantation, corresponding to an IR of transplantation of 25.4 per 100 patient-years. Five-year survival on LVAD support was 64%, with patients censored at LVAD explantation for recovery or transplantation. LVAD-related complications included bleeding (48%), infection (50%), ischaemic stroke (12%) and right ventricular failure (39%). Survival did not differ by LVAD indication (bridge-to-transplant as reference, adjusted HR 0.62, 95% CI 0.14\u20132.72).\nCONCLUSIONS: In this contemporary, real-world, medium-sized cohort, HeartMate 3 therapy provided durable long-term support across a broad spectrum of advanced heart failure patients, with outcomes consistent with those reported in large multicentre registries.<\/jats:p>","DOI":"10.57187\/5384","type":"journal-article","created":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T19:20:12Z","timestamp":1792437612000},"page":"5384","source":"Crossref","is-referenced-by-count":0,"title":["Contemporary outcomes after 100 consecutive HeartMate 3 LVAD implantations: a single-centre cohort study from a Swiss tertiary centre"],"prefix":"10.57187","volume":"156","author":[{"given":"Anna","family":"Nowacka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Hullin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Yerly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamila","family":"Abdurashidova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Marcucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Rancati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyril","family":"Moulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas","family":"Liaudet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zied","family":"Ltaief","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Kirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9074-6505","authenticated-orcid":false,"given":"Henri","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36756","published-online":{"date-parts":[[2026,10,19]]},"container-title":["Swiss Medical Weekly"],"original-title":[],"link":[{"URL":"https:\/\/smw.ch\/index.php\/smw\/article\/download\/5384\/6731","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/smw.ch\/index.php\/smw\/article\/download\/5384\/6732","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/smw.ch\/index.php\/smw\/article\/download\/5384\/6731","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T19:20:12Z","timestamp":1792437612000},"score":1,"resource":{"primary":{"URL":"https:\/\/smw.ch\/index.php\/smw\/article\/view\/5384"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,19]]},"references-count":0,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.57187\/5384","relation":{},"ISSN":["1424-3997"],"issn-type":[{"value":"1424-3997","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,19]]}}}